Castle Biosciences Stock Performance
| CSTL Stock | USD 17.60 0.58 3.41% |
The firm shows a Beta (market volatility) of 0.95, which signifies possible diversification benefits within a given portfolio. Castle Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Castle Biosciences is expected to follow. At this point, Castle Biosciences has a negative expected return of -0.0699%. Please make sure to confirm Castle Biosciences' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Castle Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Castle Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent basic indicators, Castle Biosciences is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors. ...more
Actual Historical Performance (%)
One Day Return 3.41 | Five Day Return 10.55 | Year To Date Return (37.23) | Ten Year Return (17.76) | All Time Return (17.76) |
1 | Acquisition by Cotton Rodney of 5329 shares of Castle Biosciences subject to Rule 16b-3 | 03/26/2025 |
2 | Castle Biosciences DecisionDx-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN... | 03/28/2025 |
3 | Disposition of 165 shares by Derek Maetzold of Castle Biosciences at 21.518 subject to Rule 16b-3 | 04/21/2025 |
4 | New Study Shows Castle Biosciences DecisionDx-Melanoma Test Ou | 04/30/2025 |
5 | Castle Biosciences Receives Price Target Adjustment by Canaccord Genuity CSTL Stock News | 05/06/2025 |
6 | Acquisition by Cotton Rodney of 1952 shares of Castle Biosciences subject to Rule 16b-3 | 05/08/2025 |
7 | Real-World Study Confirms Long-Term Performance of DecisionDx-U | 05/09/2025 |
8 | Top NASDAQ Stocks Spotlight on Castle Biosciences | 05/13/2025 |
9 | Disposition of tradable shares by Derek Maetzold of Castle Biosciences at 29.48 subject to Rule 16b-3 | 05/15/2025 |
10 | Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference | 05/21/2025 |
11 | Acquisition by Harrison Miles of 13667 shares of Castle Biosciences subject to Rule 16b-3 | 05/22/2025 |
12 | Disposition of 8673 shares by Goldberg Ellen of Castle Biosciences subject to Rule 16b-3 | 05/23/2025 |
13 | New Data at ASCO 2025 Affirms DecisionDx-Melanomas Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes | 05/29/2025 |
14 | CSTL to Join KeyBancs New York Dinner Meeting for Investors CSTL Stock News | 06/02/2025 |
15 | Castle Biosciences Founder, President and CEO Derek Maetzold Ho | 06/04/2025 |
| Begin Period Cash Flow | 98.8 M |
Castle Biosciences Relative Risk vs. Return Landscape
If you would invest 1,893 in Castle Biosciences on March 10, 2025 and sell it today you would lose (133.00) from holding Castle Biosciences or give up 7.03% of portfolio value over 90 days. Castle Biosciences is currently does not generate positive expected returns and assumes 2.9661% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than Castle, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Castle Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Castle Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Castle Biosciences, and traders can use it to determine the average amount a Castle Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0236
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CSTL |
Estimated Market Risk
| 2.97 actual daily | 26 74% of assets are more volatile |
Expected Return
| -0.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Castle Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Castle Biosciences by adding Castle Biosciences to a well-diversified portfolio.
Castle Biosciences Fundamentals Growth
Castle Stock prices reflect investors' perceptions of the future prospects and financial health of Castle Biosciences, and Castle Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Castle Stock performance.
| Return On Equity | -0.012 | ||||
| Return On Asset | -0.018 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | (0.32) % | ||||
| Current Valuation | 258.85 M | ||||
| Shares Outstanding | 28.87 M | ||||
| Price To Earning | 87.86 X | ||||
| Price To Book | 1.15 X | ||||
| Price To Sales | 1.46 X | ||||
| Revenue | 332.07 M | ||||
| Gross Profit | 284.39 M | ||||
| EBITDA | 38.14 M | ||||
| Net Income | 18.25 M | ||||
| Cash And Equivalents | 273.17 M | ||||
| Cash Per Share | 10.39 X | ||||
| Total Debt | 26.34 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 11.08 X | ||||
| Book Value Per Share | 15.27 X | ||||
| Cash Flow From Operations | 64.87 M | ||||
| Earnings Per Share | (0.19) X | ||||
| Market Capitalization | 508.15 M | ||||
| Total Asset | 531.24 M | ||||
| Retained Earnings | (200.13 M) | ||||
| Working Capital | 310.76 M | ||||
| Current Asset | 125.89 M | ||||
| Current Liabilities | 13.31 M | ||||
About Castle Biosciences Performance
By examining Castle Biosciences' fundamental ratios, stakeholders can obtain critical insights into Castle Biosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Castle Biosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 49.32 | 43.45 | |
| Return On Tangible Assets | 0.04 | 0.05 | |
| Return On Capital Employed | 0.02 | 0.02 | |
| Return On Assets | 0.03 | 0.04 | |
| Return On Equity | 0.04 | 0.04 |
Things to note about Castle Biosciences performance evaluation
Checking the ongoing alerts about Castle Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Castle Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Castle Biosciences generated a negative expected return over the last 90 days | |
| Over 93.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Castle Biosciences Founder, President and CEO Derek Maetzold Ho |
- Analyzing Castle Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Castle Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Castle Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Castle Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Castle Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Castle Biosciences' stock. These opinions can provide insight into Castle Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share (0.19) | Revenue Per Share | Quarterly Revenue Growth 0.206 | Return On Assets |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.